Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | CDK4 | P11802 | 2/20 | 0.53 |
| ▸ | CCND1 | P24385 | 2/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224795 | 0.90 | EGLN1 (0.47) | MEN1KMT2ASIRT1SMN1; SMN2PTGS2 | |
| SCHEMBL5228962 | 0.86 | PTGS2 (0.65) | MEN1KMT2ASIRT1SMN1; SMN2PTGS2 | |
| SCHEMBL4064897 | 0.81 | HIF1A (0.52) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4058387 | 0.80 | EGLN1 (0.70) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL28674794 | 0.77 | PTGS2 (0.75) | MEN1KMT2ASIRT1PTGS2PTGS1 | |
| SCHEMBL5231051 | 0.77 | PTGS2 (0.77) | MEN1KMT2ASIRT1SMN1; SMN2PTGS2 | |
| SCHEMBL13824295 | 0.77 | MEN1 (0.58) | MEN1KMT2ASIRT1SMN1; SMN2PTGS2 | |
| SCHEMBL28358519 | 0.76 | SMN1; SMN2 (0.77) | MEN1KMT2ASIRT1SMN1; SMN2PTGS2 | |
| SCHEMBL29650351 | 0.76 | SMN1; SMN2 (0.77) | MEN1KMT2ASIRT1SMN1; SMN2PTGS2 | |
| SCHEMBL4066916 | 0.76 | EGLN1 (0.61) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | claimed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | claimed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | disclosed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | POLI, DUT, NAAA | MEN1 3914/4885KMT2A 91/4885SIRT1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.